Novo Nordisk A/S $NVO Shares Sold by Hemenway Trust Co LLC

Hemenway Trust Co LLC lowered its holdings in Novo Nordisk A/S (NYSE:NVO) by 36.8% during the third quarter, Holdings Channel reports. The fund owned 78,167 shares of the company’s stock after selling 45,561 shares during the quarter. Hemenway Trust Co LLC’s holdings in Novo Nordisk A/S were worth $4,337,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Revolve Wealth Partners LLC raised its stake in shares of Novo Nordisk A/S by 8.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock valued at $214,000 after buying an additional 200 shares during the last quarter. AQR Capital Management LLC raised its position in Novo Nordisk A/S by 21.0% during the first quarter. AQR Capital Management LLC now owns 62,099 shares of the company’s stock valued at $4,312,000 after acquiring an additional 10,758 shares in the last quarter. Sivia Capital Partners LLC lifted its holdings in Novo Nordisk A/S by 18.2% in the second quarter. Sivia Capital Partners LLC now owns 10,320 shares of the company’s stock valued at $712,000 after acquiring an additional 1,587 shares during the period. Cullen Frost Bankers Inc. grew its stake in shares of Novo Nordisk A/S by 0.9% during the 2nd quarter. Cullen Frost Bankers Inc. now owns 117,889 shares of the company’s stock worth $8,137,000 after purchasing an additional 1,060 shares during the period. Finally, Brookstone Capital Management grew its stake in shares of Novo Nordisk A/S by 55.3% during the 2nd quarter. Brookstone Capital Management now owns 22,037 shares of the company’s stock worth $1,521,000 after purchasing an additional 7,848 shares during the period. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts recently issued reports on NVO shares. TD Cowen reissued a “buy” rating on shares of Novo Nordisk A/S in a report on Tuesday, February 3rd. HSBC reissued a “hold” rating and set a $54.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, December 10th. CICC Research assumed coverage on Novo Nordisk A/S in a report on Friday, January 9th. They issued an “outperform” rating and a $73.50 price target for the company. Argus reissued a “hold” rating on shares of Novo Nordisk A/S in a report on Monday, December 8th. Finally, Weiss Ratings upgraded Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, February 5th. Seven research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Novo Nordisk A/S has an average rating of “Hold” and an average price target of $56.07.

Novo Nordisk A/S Stock Down 1.6%

NYSE NVO opened at $48.46 on Friday. Novo Nordisk A/S has a one year low of $43.08 and a one year high of $93.80. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.57 and a current ratio of 0.80. The business has a fifty day moving average price of $53.82 and a 200 day moving average price of $53.21. The company has a market cap of $216.38 billion, a P/E ratio of 13.97 and a beta of 0.67.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, beating analysts’ consensus estimates of $0.90 by $0.11. The business had revenue of $12.43 billion during the quarter, compared to analysts’ expectations of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. Research analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The business also recently announced a dividend, which will be paid on Wednesday, April 8th. Stockholders of record on Monday, March 30th will be issued a dividend of $1.2751 per share. This represents a dividend yield of 541.0%. The ex-dividend date is Monday, March 30th. Novo Nordisk A/S’s payout ratio is currently 23.63%.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.